Galvus licensed as monotherapy for type II diabetes

Galvus (vildagliptin) is now licensed as monotherapy for the treatment of type II diabetes in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

Galvus as monotherapy now an option in type II diabetes
Galvus as monotherapy now an option in type II diabetes

In studies as monotherapy, vildagliptin improved glycaemic control whilst being generally well tolerated compared with placebo, metformin and gliclazide. It had minimal effect on weight gain.

Galvus is also licensed for dual therapy of type II diabetes and has recently been approved for use in patients with renal impairment.

View Galvus drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...